According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Vertex Pharmaceuticals continues to develop therapies where there is a need. Veeva Systems has a long runway for growth in its niche of the cloud market. Equity markets have been seesawing for the ...

Kewalramani emigrated to the United States at the age of 11, and is now the first female CEO of a large, public U.S. biotechnology company Vertex Pharmaceuticals. "Under her leadership ...

Ten healthcare organizations were recognized on LinkedIn’s 2025 list of the best large employers for career growth. The ninth annual ranking evaluates companies with 5,000 or more global ...

volume and implied volatility for Vertex Pharmaceuticals Inc. Evaluate the prices and premiums associated with these options to make informed decisions about your trading strategies. Quotes and ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...